Clinical insight
Novel Coronavirus Information Center
Elsevier’s free health and medical research on the novel coronavirus (SARS-CoV-2) and COVID-19
Welcome to Elsevier's Novel Coronavirus Information Center. Here you will find expert, curated information for the research and health community on SARS-CoV-2 (the novel coronavirus) and COVID-19 (the disease).
All resources are free to access and include guidelines for clinicians and patients.
See our directory of all Elsevier's COVID-19 resources
For researchers
Under the Research tab, you will find the latest early-stage and peer-reviewed research on COVID-19 from journals including The Lancet and Cell Press. We have also made related articles and book chapters free to access on ScienceDirect.
View free articles on ScienceDirect
These articles are also available to download over FTP with rights for full text and data mining, re-use and analyses for as long as needed.
- Server address: coronacontent.np.elsst.com
- Protocol: sftp (SSH File Transfer Protocol)
- Username: public
- Password: beat_corona
You will need to use FTP client software such as Cyberduck or WinSCP to access the FTP server.
Download full text for data mining
We are also giving free access to Elsevier's clinical, biomedical and life sciences research resources and solutions to researchers focused on coronavirus drugs and vaccines or clinical research.
For clinicians
Under the Clinical information tab, you will find evidence-based skill guides and care plans for treatment, safety and patient education, along with emergency prepared webinars by the CDC.
For patients
In the Patient resources section, you can find our 3D4Medical coronavirus video, resources from the CDC and WHO, and information about Elsevier's Patient Access Program for research.
Share your feedback to help us improve our Novel Coronavirus Information Center. And if you experience any accessibility problems with the site or content, please contact accessibility@elsevier.com.
Introduction
Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier
Clinical information
In this section, you can find the following resources:
- Guidelines: including new NIH and NICE guidelines; COVID-19 guidance on testing, drug therapy, ventilators, PPE, cardiovascular medicine and anesthesiology; and videos on medical procedures.
- Elsevier Clinical Solutions: Clinical Overviews on ClinicalKey, Clinical Skills for Nursing, Interprofessional Care Plans and patient engagement resources
- Mental and behavioral health: Guidance for anxiety and depression, including Patient Engagement videos
Elsevier COVID-19 Healthcare Hub
Gain access to our latest evidence-based practices and resources for COVID-19, covering topics from symptom management to diagnosis, treatment and ongoing wellness.
New podcast series
Expert Insights on COVID-19 with Elsevier
Webinar: COVID-19 — global perspectives and the transformation of US healthcare
In this free webinar, hosted by the Editorial Team of Healthcare: The Journal of Delivery Science and Innovation, two experts examine how COVID-19 is changing healthcare around the world. Dr. Ashish Jha looks at lessons learned from other countries and how they inform our approach to managing this and future pandemics. Bryony Winn discusses how lessons learned from COVID will influence US healthcare delivery for years to come. Register here
Guidelines
Guidelines for clinical practice, lab testing, equipment and more
Elsevier Clinical Solutions
Guidance from ClinicalKey, Clinical Solutions Nursing, Interprofessional Practice and Patient Education
Mental and behavioral health
With the fear and uncertainty brought on by the pandemic — and calls for social distancing — many people are experiencing increased stress, anxiety and depression. Our evidence-based patient education resources support professional practice guidelines, presenting information in a way that is easy to understand and actionable. You can find more resources in Elsevier's COVID-19 Healthcare Hub.
Anxiety resources
Anxiety screening tool
Elsevier has created this anxiety screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 13 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.
Clinical Skills
- Anxiety – Adults
- Anxiety: Adolescents
- Generalized Anxiety Disorder
- Generalized Anxiety Disorder Management
Clinical Overviews
Interprofessional Care Planning
Clinical eLearning
Patient Education
Anxiety literature
Book chapters and peer-reviewed articles from Elsevier journals
Depression resources
Depression screening tool
Elsevier has created this depression screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 18 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.
Clinical Skills
Clinical Overviews
Patient Education
Depression literature
Book chapters and peer-reviewed articles from Elsevier journals
Related stories by Elsevier book authors
Clinical insight
COVID-19 and loneliness: Can we do anything about it?
Clinical insight
6 evidence-based methods to head off COVID-19-related depression and anxiety
Video: How Fangcang Shelter Hospitals function in combating COVID-19
With Chen Wang, MD, PhD, FCCP, President of the Chinese Academy of Medical Sciences | April 1, 2020
Chinese-language resources
中文资源
Resources from Elsevier's Clinical Solutions team in China
全球冠状病毒研究机构及研究人员分布图
基于爱思唯尔独有的全球最大的引文摘要数据库Scopus
Research
In this section, you can find the following resources:
- Journal articles, including coronavirus hubs by The Lancet and Cell Press
- Early-stage research (preprints on SSRN)
- Infographic: global research trends in infectious disease
- Resources for drug discovery
- Interactive map: global disease outbreak experts
Related articles freely available on ScienceDirect
Elsevier has made coronavirus-related articles freely available for as long as is necessary, commencing in February 2020.
The Lancet Coronavirus Hub
The Lancet's Coronavirus hub page brings together new coronavirus content from The Lancet journals as it is published.
Cell Press Coronavirus Resource Hub
On this Coronavirus Resource Hub, curated by members of the Cell Press editorial team, you'll find content about the outbreak as it appears in Cell Press journals along with our policies for submitting papers.
1Science Coronavirus Research Repository
1science, acquired by Elsevier in 2018, was created to expand the scope of existing abstracting and analytics databases. It includes quality controlled academic and research documents in all disciplines and languages, from all countries. Its core index, 1findr, currently comprises more than 120 million metadata records, including over 30 million links to free full-text articles selected from about 100,000 referred scholarly journals. The Coronavirus Research Repository is a custom extraction from 1findr comprising articles on COVID-19, MERS, SARS and coronaviruses in general.
Centre d’information sur le nouveau coronavirus
This French version of our Novel Coronavirus Information Center includes regular updates on research in French journals.
Call for papers
Various Elsevier journals have special issues related to COVID-19
Content hubs from other publishers
Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | American College of Cardiology| Chongqing VIP Information. Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.
You can find all these publishers and more on LitCovid — the National Library of Medicine's curated hub of scientific literature about novel coronavirus. It currently provides access to more than 3,200 articles in PubMed and is being updated daily.
Early-stage research: preprints on SSRN
Rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.” SSRN , Elsevier’s platform for the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.
View coronavirus research on SSRN
Top 10 SSRN downloads of the week*
- Human Mobility Restrictions and the Spread of the Novel Coronavirus (2019-nCoV) in China 245
- The Potential Public Health and Economic Value of a Hypothetical COVID-19 Vaccine in the United States: Use of Cost-Effectiveness Modeling to Inform Vaccination Prioritization 28
- Quantifying the Effects of Social Distancing on the Spread of COVID-19 22
- An Ecological Study Assessing the Relationship between Public Health Policies and Severity of the COVID-19 Pandemic 20
- The 'Great Lockdown': Inactive Workers and Mortality by COVID-19 19
- Smoking and Risk of Negative Outcomes Among COVID-19 Patients: A Systematic Review and Meta-Analysis 19
- Is Karachi Knocking at Herd Immunity? A Possible Reason for Decline in SARS-CoV-2 Infections 15
- Persistent Inflammatory Interstitial Lung Disease Following SARS-CoV-2 Infection at 6 Weeks Post Discharge Responds Rapidly to Oral Corticosteroids 15
- Analysis of Asymptomatic COVID-19 Patients to Minimize Viral Transmission: A Prospective Cohort Study 14
- Psychological Wellbeing During the Global COVID-19 Outbreak 13
* Calculated on Friday, Oct. 2
Infographic: Global research trends
Infographic: global research trends in infectious disease
Download Elsevier’s infographic on infectious disease research trends, top research orgs and the impact of outbreaks
Resources for drug discovery
New review of hydroxychloroquine prophylaxis clinical trials
The detailed analysis of clinical trials aims to give an overall picture of HCQ use as a COVID-19 prophylaxis around the world.
- Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020, One Health (Mary 19, 2020)
Free access to biomedical tools via Elsevier's Coronavirus Research Hub
Elsevier is offering researchers free access to a collection of clinical, biomedical and life sciences research resources and solutions for coronavirus research through October 28, 2020. These may be used by academic, government, not-for-profit and commercial researchers. We will initially give priority to researchers working on vaccine, drug and clinical research while working to increase the capacity of the platform for further use cases. The Hub includes access to ClinicalKey, Embase, SSRN, Mendeley Data, the ScienceDirect Covid-19 collection, Elsevier Text Mining (ETM), Mendeley and the Pure Covid-19 Portal. We plan to bring Reaxys and Veridata EDC online shortly. Visit Elsevier's Coronavirus Research Hub
R&D tool to capture clinical trial data is free for researchers studying COVID-19
Elsevier recently launched Veridata Electronic Data Capture (EDC), which enables clinical researchers to capture clinical trial data in a secure environment. To assist researchers working to develop vaccines and other therapies for COVID-19, Elsevier has pledged to make Veridata EDC available for free. Interested clinical researchers can contact Elsevier customer support via e-mail at covid19@elsevier.com and apply for a demo account. Following the necessary compliance training, they will receive a free 12-month license. Read the press release
Gender and COVID-19 Group on Mendeley
This collection of research, studies and other references covers the sex and gender dimensions of the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. The library is a public group, free for anyone in the world to join, access and add. References - articles, preprints, news articles, blog posts, magazine articles, reports, etc - include those compiled by Dr. Rosemary Morgan at Johns Hopkins University and colleagues from the Gender and COVID-19 Working Group, as well as those from other compilations and sources. The library on the Mendeley platform includes >500 references related to Gender and COVID-19, as well as gender and other infectious disease/epidemics, which you can locate and find resources, include direct citations and references within your work, and add additional references & folders directly to the group. We invite the community to continue posting new references as they’re published/become available even if also being added to an existing compilation elsewhere.
Hydroxychloroquine and the coronavirus: connecting the dots through the Biology Knowledge Graph
A new analysis aims to identify the effects of hydroxychloroquine and Azithromycin on proteins known to be up-regulated by severe Acute respiratory distress syndrome (ARDS) using Elsevier’s Biology Knowledge Graph. Read more on Elsevier's Pharma R&D Today blog
COVID-19 drug therapy — updated on August 28
Pharmacists in Elsevier's Clinical Solutions group write about potential treatment options for COVID-19. Read their paper.
Drug information from Elsevier's R&D Solutions
Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we use those tools to generate information relevant to combating COVID-19:
- 121 drugs and natural products successfully used against previous coronavirus infections including SARS. This list was generated using Elsevier's Pathway Studio.
- 393 substances that interact with 25 targets related to 6 target species including SARS coronavirus, Middle East respiratory syndrome coronavirus, human Middle East respiratory syndrome coronavirus, Human coronavirus 229E, Coronaviridae and Coronavirinae, with normalized affinity value > 6. This list was generated using Elsevier’s Reaxys Medicinal Chemistry.
- Autophagy is a cellular recycling process, whereby cells eliminate damaged or diseased components in order to regenerate and build new healthier cells; thus, viruses are usually identified and disposed of in this way. Would it be possible to induce the autophagy process and limit the viral infection by using some substances? Pathway Studio provides a list of 406 compounds that have been reported inhibiting autophagy pathway, and their related references as well as a list of 802 compounds that have activating roles in autophagy.
Mayo Clinic Proceedings: Possible COVID-19 Pharmacotherapies and QTc/TdP Liability
The Mayo Clinic Proceedings journal has released a pre-proof of a new paper titled Possible COVID-19 Pharmacotherapies and QTc/TdP Liability. From the abstract: "As the COVID-19 global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the “off label” re-purposing of drugs such as hydroxychloroquine and lopinavir/ritonavir with the potential for unwanted QT interval prolongation, and a risk of drug induced sudden cardiac death. With the possibility that a significant proportion of the world’s population could receive soon COVID-19 pharmacotherapies with torsadogenic potential for therapy or post-exposure prophylaxis, this document serves to help healthcare providers mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk to personnel of COVID 19 exposure and conserving the limited supply of personal protective equipment. Read the paper
Interactive map: global coronavirus experts
This map represents the most active institutions researching COVID-19 and related coronaviruses. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications related to COVID-19, coronaviruses and related diseases such as SARS and MERS. We then used the resulting ~28,000 publications to identify the currently active researchers and institutions that are working in these areas, the map shows the most prolific global institutions and links to their authors. (Updated: October 1, 2020)
Click on a pin to see more about the institution, the numbers of researchers and their publications that matched our query in Scopus. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.
Pure portal: Discover research collaborators and institutions globally
Use this Pure portal to discover novel coronavirus related research collaborators and institutions around the world. It uses Elsevier’s Natural Language Fingerprinting technology, scientific taxonomies and Scopus profiles and can be used to filter and find associated publications.
Public health
Here, you will find guidance and commentary from experts along with official guidance from major health organizations such as the CDC and WHO. For research on public health and related topics, see our Research section.
Join us for the 14th Vaccine Congress Online Edition
The 14th Vaccine Congress – Online Edition: Combatting the threat of Covid-19 will take place on September 28-29 and will be available afterwards on demand. The focus will be on combatting the threat of Covid-19, with leading experts in vaccinology sharing their knowledge on the current developments and challenges we face. Participation is free. Register here
Research insight
A serendipitous discovery advances COVID research – and makes a cameo in Congress
“This is work we really need to pursue,” Dr. Fauci says, touting findings that T cells from common coronaviruses may offer protection against COVID-19
Dr. Fauci features Cell paper in Congressional hearing
There are two limbs of the immune response. One is an antibody, which is a protein that is made by the cells of the body to bind to the virus and is usually the hallmark of protection against infection. (The other is) the cellular immune response of T cells, and those T cells have the capability of essentially suppressing or killing cells that are infected and preventing the cells that are infected form making new viruses.
Then, holding up a copy of an article in the journal Cell, Dr. Fauci pointed out the finding that people who have not been exposed to SARS-Cov-2 but were exposed to other coronaviruses, such as those that cause the common cold, have T cells with cross-reactivity to SARS-Cov-2.
This is work we really need to pursue; we’re just at the cusp of understanding his type of response in Covid-19.
This finding could explain why some people are much more affected by COVID-19 than others – and how vaccines could function to be more effective.
The research has been featured on CNN.
Read the paper
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Cell (May 14, 2020)
COVID19 in America: An October Plan
New in Microbes and Infection: Prof. Peter Hotez, MD, PhD, of Baylor College of Medicine describes his “October Plan” to help the United States — including its school teachers — safely return to work. Dr. Hotez is Professor of Pediatrics and Molecular Virology & Microbiology and Dean of the National School of Tropical Medicine at Baylor College of Medicine, where he is also Co-Director of the Texas Children’s Center for Vaccine Development. Read his commentary
Podcast: Richard Horton on COVID-19 vaccines
The Lancet Editor-in-Chief Richard Horton explains the current status of the Oxford and China COVID-19 vaccines, including an overview of current progress and the next steps for both. Listen here
Related papers
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, The Lancet (July 20, 2020)
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet (July 20, 2020)
Webinar: COVID-19: how can we better integrate health and disaster management?
Disaster Science experts Prof. Rajib Shaw and Prof. David Alexander (both Editors-in-Chief of key disaster science journals) will outline how the Disaster Risk community could better respond to future pandemics in the wake of COVID-19.
- Prof. Shaw will focus on specific guidelines the UN is working on for how national governments should integrate biological hazards into Disaster Risk Reduction strategies, as well as the experience of dealing with COVID-19 in Japan and East Asia.
- Prof. Alexander will discuss key aspects of emergency planning and management for pandemics.
The webinar is Thursday, July 16 at 12 noon BST | 1 pm CET | 7 am EST | 7 pm Beijing | 8 pm Tokyo. Register here
Studies to improve face masks and disinfect the air
- In a new article in Materials Today Physics, researchers describe their air disinfection system to control the spread of COVID-19, for which they filed a provisional patent application: Catching and killing of airborne SARS-CoV-2 to control spread of COVID-19 by a heated air disinfection system (July 7, 2020)
- In Open Ceramics, researchers describe a sputtered antimicrobial/virucidal silver nanoclusters/silica composite coating to significantly improve the protection capacity of face masks while also being suitable for coating air filters and other surfaces: Virucidal effect against Coronavirus SARS-CoV-2 of a silver nanocluster/silica composite sputtered coating (June 6, 2020)
Special issue: Bioaerosol and infectious diseases
This special issue in the Journal of Aerosol Science, from 2018, has articles that are relevant to COVID-19.
COVID-19 Pandemic Collection in AJPM
View this collection in the American Journal of Preventive Medicine
New study on economic impact of COVID-19
A study in the Journal of Accounting and Public Policy — Estimating the COVID-19 cash crunch: Global evidence and policy — investigates how the health crisis could affect the liquidity of firms in 26 countries. In the most adverse scenario, the average firm with a limited ability to adapt production would exhaust its cash holdings in about two years. This paper also compares different fiscal policies that governments could implement to mitigate the liquidity risk.
New test for COVID-19 may deliver faster results to more people
Scientists in Korea have developed a novel assay capable of detecting the causative viral pathogen of COVID-19 that can be run in decentralized test facilities. Read their study in The Journal of Molecular Diagnostics.
COVID-19 Data Insights Map by LexisNexis Risk Solutions
By combining their data and analytics with those of other industry stakeholders, LexisNexis Health Care created a COVID-19 dataset and interactive visualization to provide insights on at-risk populations and care capacity risks. View the map
Predictive models for the COVID-19 pandemic – a basis for decision-making
Ursula von Schenck, MD, Medical Officer, Elsevier Health Analytics | March 27, 2020
Podcast: Richard Horton on COVID-19 vaccines
The Lancet Editor-in-Chief Richard Horton explains the current status of the Oxford and China COVID-19 vaccines, including an overview of current progress and the next steps for both. Listen here
Related papers
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, The Lancet (July 20, 2020)
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet (July 20, 2020)
Progress in Disaster Science: COVID-19 Special Collection
Keeping wider disciplinary involvement in mind, the journal Progress in Disaster Science plans to publish special issues as a major learning from the evolving nature of the pandemic. Papers on the following topics related to COVID-19 response are encouraged: public health response, governance and policy analysis, emerging technologies, roles of civil societies and other stakeholders, citizen participation, collateral hazards, business continuity, recovery planning, economic/fiscal implications. Read the special collection
Journal of Aerosol Science: Special section on "Virus Aerosol Science, Sampling, and Control"
The editor, Prof. Chris Hogan, writes: "The Journal of Aerosol Science has long been a resource on understanding viruses in aerosols, methods to sample airborne viruses, and to control and inactivate airborne viruses. In this collection, we highlight numerous studies over the past decade focusing on virus aerosol science. In addition, we invite authors to contribute this virtual collection by submitting to this journal, selecting the option: "SARS-CoV-2 & Virus Aerosols." Read the special section
Why COVID-19 antibody testing is crucial — and what's needed for it to be effective
By David Wild, Editor, The Immunoassay Handbook | April 16, 2020
Complexities of epidemics
Thomas P. Erlinger, MD, MPH | VP, Clinical Analytics, Elsevier | March 18, 2020
COVID-19 podcasts and webinars by CIDRAP
Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here
More public health resources
- Disaster Epidemiology and Surveillance, Chapter 27, Jekel's Epidemiology, Biostatistics, Preventive Medicine, and Public Health, 5th Edition (Elsevier, 2020)
- Impacts on Society and Economy (OECD)
- Interactive map showing global spread of COVID-19 (WHO)
- Interactive map shows global spread of the virus (Johns Hopkins CSSE)
- Guidance for businesses and employers (CDC)
- Travel precautions (CDC)
- Information and updates (CDC)
- Novel coronavirus advice for the public (WHO)
- Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance (WHO)
- National Genomic Data Center (China) 2019 nCoV Resource Center (新型冠状病毒信息库)
Official coronavirus guidance from various countries:
Argentina | Australia | Canada | Chile | China | Colombia | France | Germany | Mexico | Peru | Singapore | Spain | UK | US
- Sources of updated information in the EU/EEA countries
- Panamerican Health Organization (Latin American branch of the WHO)
Patient resources
عدوى فيروس كورونا المستجد (patient education in Arabic)
Elsevier's Patient Access Program for research
With our Patient Access Program, patients and their caregivers can receive medical or healthcare related research papers by emailing patientaccess@elsevier.com. This email is constantly monitored by our support teams, who aim to provide individual articles at no cost to patients and caregivers within 24 hours. Requesters simply need to include the article title and authors, date published, and/or the DOI or URL if available so we can locate the article as quickly as possible. Learn more
COVID-19 podcasts and webinars
Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here
More resources
- Novel coronavirus advice for the public (WHO)
- Travel precautions (CDC)
- See our Patient Education resources under Mental & Behavioral Health
Usage notice
Since January 2020, Elsevier has created an online resource center with free information in English and Mandarin on the novel coronavirus (COVID-19).
This Novel Coronavirus Information Center is hosted on Elsevier Connect, the company’s public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource center — including this research content — immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource center remains active.
Contributors